Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

ABSTRACT:

Objectives

New data suggest that glioma stem-like cells (GSCs) and neural stem/progenitor cells (NSCs) may share common origins. GSCs drive tumor proliferation and appear to be resistant to classic chemotherapy, while the effects of chemotherapy on NSCs are not well studied. As the role of NSCs in learning and memory is increasingly recognized, we need to identify drugs that reduce neurotoxicity but are still effective against glial tumors.

Methods

We treated 3 human NSC cultures and multiple low- and high-grade GSC cultures with the commonly used agents temozolomide (TMZ) and cisplatin (CIS), and with 2 newer, promising drugs: the proteasome inhibitor bortezomib (BTZ) and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL). We measured cell surviv

SUBMITTER: Gong X 

PROVIDER: S-EPMC3269770 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature